These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28566196)

  • 1. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam A; Jahnke N; Remmington T; Southern KW
    Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196
    [No Abstract]   [Full Text] [Related]  

  • 2. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataluren in cystic fibrosis: development, clinical studies and where are we now?
    Zainal Abidin N; Haq IJ; Gardner AI; Brodlie M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1363-1371. PubMed ID: 28730885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ignoring the nonsense: a phase II trial in cystic fibrosis.
    Hyde SC; Gill DR
    Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.
    Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E
    Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
    Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
    Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).
    Konstan MW; VanDevanter DR; Rowe SM; Wilschanski M; Kerem E; Sermet-Gaudelus I; DiMango E; Melotti P; McIntosh J; De Boeck K;
    J Cyst Fibros; 2020 Jul; 19(4):595-601. PubMed ID: 31983658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems.
    Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
    O'Sullivan BP
    Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of the basic defect in cystic fibrosis.
    Roomans GM
    Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.
    Boyle MP; De Boeck K
    Lancet Respir Med; 2013 Apr; 1(2):158-63. PubMed ID: 24429096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
    Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of CFTR protein in human leukocytes by flow cytometry.
    Johansson J; Vezzalini M; Verzè G; Caldrer S; Bolognin S; Buffelli M; Bellisola G; Tridello G; Assael BM; Melotti P; Sorio C
    Cytometry A; 2014 Jul; 85(7):611-20. PubMed ID: 24623386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.